Rocket Pharmaceuticals secures $180M cash injection via regulatory voucher sale
Rocket Pharmaceuticals (NASDAQ:RCKT) completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV), generating $180 million in gross, non-dilutive cash proceeds.


_1420153_640x360_2503423555750-640x360.webp&w=3840&q=75)


_1420139_640x360_2503419971718-640x360.webp&w=3840&q=75)




_1420095_640x360_2503417923853-640x360.webp&w=3840&q=75)
